MedTrace Logo

Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana

NCT05952141 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 610

Last updated 2026-03-30

No results posted yet for this study

Summary

Investigators will test the effectiveness of adaptive strategies on timely adoption of cervical cancer treatment in Botswana using a pragmatic trial design.

Conditions

Interventions

BEHAVIORAL

Clinic Outreach

A member of the pathology team will contact the referring clinic to communicate the readiness of results.

BEHAVIORAL

Enhanced Outreach

A member of the pathology team will contact both the referring clinic and the patient directly to communicate the readiness of results.

BEHAVIORAL

Low-Touch Strategy

Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging.

BEHAVIORAL

High-Touch Strategy

Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging in combination with synchronous telephone-based patient navigation.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Botswana

    collaborator OTHER

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Katharine Rendle, PhD,MSW,MPH · University of Pennsylvania

  • Surbhi Grover, MD, MPH · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2026-12-31
Completion
2027-08-31

Countries

  • United States
  • Botswana

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05952141 on ClinicalTrials.gov